% | $
Quotes you view appear here for quick access.

Thermo Fisher Scientific, Inc. Message Board

  • stengaard_dk stengaard_dk Jun 17, 2012 7:07 PM Flag

    Phadia lost the case friday

    Friday saw a verdict in the long running courtcase (6 years) between swedish Phadia and danish Bioporto.

    Phadia (now owned by Thermo Fischer) had a patent on NGAL - supposedly covering all human diseases. The patent has never been used actively by Phadia, but the rights to pursue the Patent has been given to Abbott - who wanted to use it as a legal base for their Architect heterogenous NGAL Test.

    friday - Phadia/
    Abbott lost the case - which ultimately will give BioPorto unhindered market access (and close the door for Abbott) a market that is potentially as large as the heartmarker Toponin..

    read about the verdict - and its implications:

138.66+0.70(+0.51%)Nov 25 4:03 PMEST